Porokeratosis
Methodology & AI Transparency ⓘ
Porokeratosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Porokeratosis (Q82.8; Children's & Adolescent Health) utilize growth-chart trajectory review [Porokeratosis Q82.8] and objective WHO / CDC in Porokeratosis (Q82.8: Age-Adjusted Growth Percentiles) targets (Consistent personal growth curve tracking (Q82.8)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Mapped to Children's & Adolescent Health under ICD-10-CM Q82.8 for Porokeratosis clinical workups.
- 3 Typical cash cost range: Primary evaluation for Porokeratosis incorporates growth-chart trajectory review [Porokeratosis Q82.8] and symptom diary review.
- 4 Top reported side effects / signs: Key Pediatrics biomarkers for Porokeratosis (Q82.8): WHO / CDC in Porokeratosis (Q82.8: Age-Adjusted Growth Percentiles) & Pediatric Hemoglobin & in Porokeratosis (Q82.8: Lead Screen) (Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q82.8)).
Ask our AI Specialists anything about Porokeratosis
What Is Porokeratosis?
Physicians managing Porokeratosis (Q82.8; Children's & Adolescent Health) utilize growth-chart trajectory review [Porokeratosis Q82.8] and objective WHO / CDC in Porokeratosis (Q82.8: Age-Adjusted Growth Percentiles) targets (Consistent personal growth curve tracking (Q82.8)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Porokeratosis (Q82.8, Pediatrics) reflects or congenital embryologic in Porokeratosis (Q82.8: structural variation). longitudinal control is benchmarked via WHO / CDC in Porokeratosis (Q82.8: Age-Adjusted Growth Percentiles).
Common Symptoms & Clinical Signs
- • Presentation of Porokeratosis (Q82.8): pediatric skin rashes, in Porokeratosis (Q82.8: gastrointestinal discomfort, or)
- • Secondary Porokeratosis clinical sign: growth velocity shifts, in Porokeratosis (Q82.8: newborn feeding/jaundice signs,)
- • Symptom flares in Porokeratosis correlating with WHO / CDC in Porokeratosis (Q82.8: Age-Adjusted Growth Percentiles) deviation outside Consistent personal growth curve tracking (Q82.8)
- • Functional pediatrics impact requiring growth-chart trajectory review [Porokeratosis Q82.8] evaluation (Q82.8)
Porokeratosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q82.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Children's & Adolescent Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: WHO / CDC in Porokeratosis (Q82.8: Age-Adjusted Growth Percentiles) | Consistent personal growth curve tracking (Q82.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pediatric Hemoglobin & in Porokeratosis (Q82.8: Lead Screen) | Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q82.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Porokeratosis
Treatment selection for Porokeratosis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Porokeratosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Phase 3 study of an Ad26.RSV.preF/RSV preF protein vaccine to evaluate the: What a 996-Participant Study Found Although vaccine efficacy could not be concluded, it was immunogenic with acceptable safety profile in both Japanese younger and older adult population. Respiratory investigation • 2025-07-15 • Phase III Randomized Trial | N = 996 | 93/100 | PMID 40319702 ↗ |
| Can This Approach Help? Inside the Latest Research on Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Pooled analyses showed a significantly higher percentage of participants with complete molluscum lesion clearance and larger reductions in lesion counts with VP-102 than with vehicle. American journal of clinical dermatology • 2021-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33599960 ↗ |
| Can This Approach Help? Inside the Latest Research on Nipocalimab Phase 3 Dose Selection for Severe Hemolytic Disease of the Fetus and Simulations incorporating PK/PD variability indicated that 45 mg/kg weekly per current weight maintained full FcRn occupancy in >95% of pregnant individuals, even with dosing delays up to 3 days. Journal of clinical pharmacology • 2026-09-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42726505 ↗ |
Porokeratosis Patient Community & “People Like Me” Threads
Filter Porokeratosis community threads and patient logs by age, biological sex, dosage, and treatment duration.